| Symbol | PGEN |
|---|---|
| Name | PRECIGEN, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, Maryland, 20876, United States |
| Telephone | +1 301 556-9900 |
| Fax | — |
| — | |
| Website | http://www.precigen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001356090 |
| Description | Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexons business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The companys collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. Additional info from NASDAQ: |
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Read moreThomasian Harry Jr. 🔴 sold 41.9K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008173
Read moreTennant Phil 🔴 sold 30.3K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008172
Read moreShah Rutul R 🔴 sold 42.7K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008170
Read moreLehr Donald P. 🔴 sold 29.1K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008169
Read moreSabzevari Helen 🔴 sold 119.2K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008168
Read morePrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Read moreThomasian Harry Jr. 🟡 adjusted position in 0 shares (1 derivative) of PRECIGEN, INC. (PGEN) Transaction Date: May 23, 2026 | Filing ID: 007845
Read moreTennant Phil 🟡 adjusted position in 0 shares (1 derivative) of PRECIGEN, INC. (PGEN) Transaction Date: May 23, 2026 | Filing ID: 007844
Read moreShah Rutul R 🟡 adjusted position in 0 shares (1 derivative) of PRECIGEN, INC. (PGEN) Transaction Date: May 23, 2026 | Filing ID: 007843
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metas… | Phase2 | Cervical Cancer | Recruiting | 2025-11-11 | 2030-11-30 | ClinicalTrials.gov |
| NCT06538480 | Zopa Retreatment and Vector Shedding in Adults With RRP | Phase4 | Recurrent Respiratory Papillomatosis | Recruiting | 2024-07-11 | 2028-12-02 | ClinicalTrials.gov |
| NCT05694364 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients … | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2023-01-25 | 2024-04-18 | ClinicalTrials.gov |
| NCT04724980 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | Phase1 | Recurrent Respiratory Papillomatosis | Active_Not_Recruiting | 2021-03-16 | 2026-06-05 | ClinicalTrials.gov |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AM… | Phase1 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2019-05-20 | 2025-08-01 | ClinicalTrials.gov |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanc… | Phase1 | Platinum-Resistant Fallopian Tube Carcinoma | Active_Not_Recruiting | 2019-04-30 | 2028-11-15 | ClinicalTrials.gov |
| NCT03751007 | A Study to Assess the Safety and Tolerability of Different Doses of AG019 Admin… | Phase1 | Diabetes type1 | Completed | 2018-10-24 | 2021-10-13 | ClinicalTrials.gov |
| NCT03409627 | Novel INXN-4001 Triple Effector Plasmid in Heart Failure | Phase1 | Heart Failure | Completed | 2018-04-09 | 2020-08-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PRGN-3005 UltraCAR-T cells | Other | Phase PHASE1 | Platinum-Resistant Fallopian Tube Carcinoma | ACTIVE_NOT_RECRUITING | NCT03907527 |
| INXN-4001 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT03409627 |
| AG019 - High Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-AG019 | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - Low Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - High Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-AG019 | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - Low Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| PRGN-3006 T Cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03927261 |
| PRGN-2012 - Phase II; Dose Level 2 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 2 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 1 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-3007 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Cyclophosphamide | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Fludarabine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| Zopapogene imadenovec (Zopa) | Other | Phase PHASE4 | Recurrent Respiratory Papillomatosis | RECRUITING | NCT06538480 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| Zopapogene imadenovec (Zopa) | DRUG | Phase PHASE4 | Recurrent Respiratory Papillomatosis | RECRUITING | NCT06538480 |
| Pembrolizumab alone | DRUG | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-3007 | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Fludarabine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| PRGN-2012 - Phase II; Dose Level 2 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 2 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 1 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-3006 T Cells | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03927261 |
| PRGN-3005 UltraCAR-T cells | BIOLOGICAL | Phase PHASE1 | Platinum-Resistant Fallopian Tube Carcinoma | ACTIVE_NOT_RECRUITING | NCT03907527 |
| INXN-4001 | BIOLOGICAL | Phase PHASE1 | Heart Failure | COMPLETED | NCT03409627 |